Huntington National Bank increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 37.3% during the second quarter, Holdings Channel reports. The fund owned 187,903 shares of the medical research company’s stock after buying an additional 51,021 shares during the period. Huntington National Bank’s holdings in Amgen were worth $28,590,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of AMGN. Oakworth Capital Inc. raised its stake in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares in the last quarter. Delta Asset Management LLC TN raised its stake in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares in the last quarter. Capital Advisors Ltd. LLC raised its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares in the last quarter. Vigilant Capital Management LLC raised its stake in shares of Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock worth $195,000 after buying an additional 33 shares in the last quarter. Finally, Calamos Wealth Management LLC acquired a new stake in shares of Amgen during the second quarter worth about $202,000. 79.15% of the stock is owned by institutional investors and hedge funds.
Amgen Inc. (NASDAQ:AMGN) traded up 0.25% during trading on Thursday, reaching $164.29. The company had a trading volume of 2,369,996 shares. Amgen Inc. has a 1-year low of $139.02 and a 1-year high of $176.85. The firm has a 50-day moving average of $170.01 and a 200-day moving average of $162.16. The stock has a market capitalization of $122.95 billion, a price-to-earnings ratio of 16.81 and a beta of 0.94.
Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.74 by $0.10. Amgen had a return on equity of 29.30% and a net margin of 33.07%. The firm had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.58 billion. During the same quarter last year, the company posted $2.57 earnings per share. The business’s revenue was up 5.9% on a year-over-year basis. On average, analysts anticipate that Amgen Inc. will post $11.35 EPS for the current fiscal year.
A number of equities research analysts recently issued reports on the company. Vetr raised Amgen from a “sell” rating to a “hold” rating and set a $171.34 price target for the company in a research note on Wednesday, August 3rd. Leerink Swann reissued a “hold” rating on shares of Amgen in a research note on Saturday, September 17th. Credit Suisse Group AG set a $206.00 price target on Amgen and gave the stock a “buy” rating in a research note on Saturday, September 17th. Robert W. Baird reaffirmed an “outperform” rating and set a $157.00 target price on shares of Amgen in a research report on Friday, August 26th. Finally, Citigroup Inc. lifted their target price on Amgen from $165.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, July 29th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $184.94.
In related news, VP Annette Louise Such sold 3,000 shares of the firm’s stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.20% of the stock is currently owned by corporate insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.